CompletedNot Applicable

A Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

United States5 participantsStarted 2026-04-16

Plain-language summary

The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla to the placebo axilla to see if there is a difference in self-perceived odor and microbiome. Participants will: * be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla) * self assess body odor * sample axilla with cotton round for 3rd party odor assessment * sample axilla with a swab for skin microbiome analysis via qPCR * self assess skin irritation

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: The subject is an adult between 18 and 70 y.o. * Skin health: The subject has no active skin conditions or lesions in the axillary region and no existing skin conditions (e.g., eczema, psoriasis, contact dermatitis). * Skin allergies: The subject has no known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs. Exclusion Criteria: * Subject is pregnant, nursing, or planning to become pregnant in the next 6 months. * Subject is an insulin-dependent diabetic. * Subject has been diagnosed or treated for cancer in the past 5 years. * Subject is currently using or has not used in the past two weeks any systemic antibiotics. * Subject is currently using or used within the last month any topical medications, over-the-counter (OTC) or prescription products on the underarms. * Subject is currently taking or plans to take during the study any anti-inflammatory for a chronic condition (except 81 mg-Aspirin per day), immunosuppressant, antihistamine, or sedative medications (i.e. containing antihistamines like Tylenol PM, Nyquil, etc.). * Subject is currently participating in another underarm clinical trial. Subjects may participate in other studies as long as the same test sites are not used or are testing similar products.

What they're measuring

Axillary odor self assessment (on 0-5 odor scale)

Timeframe: At baseline (before application), immediately after first application, Day 1 PM, Day 2 AM, and Day 2 PM; then once a day (PM) for Days 3-12

Trial details

NCT IDNCT07547761

SponsorKingdom

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05-04